Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form
- People whose general health and ability to carry out daily activities is rated as fully active or restricted only in physically strenuous activity (this is measured using a standard oncology scoring scale called ECOG, with a score of 0 or 1)
- People who have been confirmed through laboratory testing to have an advanced solid tumour cancer that has continued to grow despite standard treatments, where standard treatments could not be tolerated, or where no standard treatment exists
- People who have a type of blood cancer called acute myeloid leukaemia (AML) that has come back or has not responded to treatment, as defined by specific medical guidelines (WHO 2016)
- People with a life expectancy of at least 3 months
- People with a solid tumour who have at least one tumour that can be measured using standard imaging criteria (confirm with trial site)
- People whose liver, kidneys, and other organs are functioning at a sufficient baseline level (confirm with trial site)
Who may not be able to join:
- People who have been diagnosed with a different type of cancer within the last 3 years
- People with a known serious allergy to the study drug or its ingredients
- People with cancer that has actively spread to the brain or spinal cord
- People with a history of inflammation around the heart or a significant fluid build-up around the heart
- People with a history of a lung condition called interstitial lung disease
- People who have had a significant active infection within the past 2 weeks
- People known to have HIV infection
- People who test positive for hepatitis B virus
- People who test positive for hepatitis C virus, or whose hepatitis C virus levels in the blood are undetectable (confirm with trial site)
- People with severe or uncontrolled other medical conditions
- People with a history of heart attack, unstable chest pain (angina), heart bypass surgery, or stroke
- People with significantly impaired heart function or serious heart disease
- People with an abnormal heart electrical reading (specifically, a QTcF measurement above 470 milliseconds) at the screening stage
- People with a history of significant blood clots or serious bleeding disorders
- People who still have side effects from previous treatments that are rated above a mild level (Grade greater than 1)
- People with a history of a blocked bile duct caused by cancer
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jacobio Pharmaceuticals, Jacobio Pharmaceuticals
Phone: 86 10 56315466
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with dose limiting toxicities
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.